Aims: Nonsteroidal anti-inflammatory drugs (
NSAIDs), among the most commonly used drugs worldwide, are associated with gastrointestinal (GI) complications that severely limit the clinical utility of this essential class of
pain medications. Here, we mechanistically dissect the protective impact of a
natural product,
malabaricone C (Mal C), on
NSAID-induced gastropathy. Results: Mal C dose dependently diminished erosion of the stomach lining and
inflammation in mice treated with
NSAIDs with the protective impact translating to improvement in survival. By decreasing oxidative and nitrative stress, Mal C treatment prevented
NSAID-induced
mitochondrial dysfunction and cell death; nuclear factor κ-light-chain enhancer of activated B cell induction, release of proinflammatory
cytokines and neutrophil infiltration; and disruptions in the
vascular endothelial growth factor/
endostatin balance that contributes to mucosal autohealing. Importantly, Mal C failed to impact the therapeutic anti-inflammatory properties of multiple
NSAIDs in a model of acute
inflammation. In all assays tested, Mal C proved as or more efficacious than the current first-line
therapy for
NSAID-dependent GI complications, the
proton pump inhibitor omeprazole. Innovation: Given that
omeprazole-mediated prophylaxis is, itself, associated with a shift in
NSAID-driven GI complications from the upper GI to the lower GI system, there is a clear and present need for novel
therapeutics aimed at ameliorating
NSAID-induced gastropathy. Mal C provided significant protection against
NSAID-induced gastric ulcerations impacting multiple critical signaling cascades contributing to
inflammation, cell loss, extracellular matrix degradation, and angiogenic autohealing. Conclusion: Thus, Mal C represents a viable lead compound for the development of novel gastroprotective agents.